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ABSTRACT 20  21 
Invasive fungal disease (IFD) can be caused by a range of pathogens. Conventional diagnosis has the 22 
capacity to detect most causes of IFD, but poor performance limits impact. The introduction of non-23 
culture diagnostics, including the detection of (1-3)-β-D-Glucan (BDG), has shown promising 24 
performance for the detection of IFD in variety of clinical settings. Recently, the Dynamiker® Fungus 25 
(1-3)-β-D-Glucan assay (D-BDG) was released as an IFD diagnostic test. This article describes an 26 
evaluation of the D-BDG assay for the diagnosis of invasive aspergillosis (IA), invasive candidiasis (IC) 27 
and Pneumocystis pneumonia (PCP) across several high-risk patient cohorts and provides 28 
comparative data with the Associates of Cape Cod Fungitell® and BioRad Platelia™ Aspergillus Ag 29 
(GM) assays. There were 163 serum samples from 121 patients tested, from 21 probable IA cases, 28 30 
proven IC cases, six probable PCP cases, one probable IFD case, 14 possible IFD cases and 64 control 31 
patients. For proven/probable IFD the mean BDG concentration was 209pg/ml, significantly greater 32 
than the control population (73pg/ml; P: <.0001). The sensitivity, specificity, and diagnostic odds 33 
ratio for proven/probable IFD was 81.4%, 78.1%, and 15.5, respectively. Significant BDG false 34 
positivity (9/13) was associated post abdominal surgery. D-BDG showed fair and good agreement 35 
with the Fungitell®, and GM assays, respectively. In conclusion, the D-BDG provides a useful adjunct 36 
test to aid the diagnosis of IFD, with technical flexibility that will assist laboratories processing low 37 
sample numbers. Further, large scale, prospective evaluation is required to confirm the clinical 38 
validity and determine clinical utility 39 
TEXT 40 The Dynamiker® Fungus (1-3)-β-D-Glucan Assay (D-BDG) (Dynamiker Biotechnology (Tianjin) 41 Co., Ltd) has recently become available in the Europe and provides technical flexibility 42 permitting frequent, cost-effective testing. A recent publication describing the performance of  43 D-BDG for the diagnosis of invasive fungal disease (IFD) reported sensitivity and specificity for 44 IFD of 81.4% and 78.1%, respectively. 1 However, sensitivity for the detection of Pneumocystis 45 
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pneumonia (PcP) was lower than expected (50%), albeit cases were limited. 1 The detection of 46 BDG to assist in the diagnosis of PcP has been widely demonstrated. Meta-analyses have 47 confirmed performance, generating sensitivity and specificity ranging from 90.8-95.5%, and 48 78.1-86.3%, respectively. 2-4 The high sensitivity and ability to exclude a diagnosis of PcP when 49 negative,  has resulted in the inclusion of BDG testing in algorithms for management of PcP. 5  50 Data from meta-analyses is encouraging, but variations in performance between different 51 comercial BDG kits needs to be determined. In one study there was no significant difference in 52 accuracy when performance was stratified according to brand.3 Accuracy is a combination of 53 both sensitivity and specificity.  Under-performance in one parameter can be masked by over 54 performance in the other, resulting in similar overall accuracy.This can be misleading if the 55 performance of one parameter is more important. This is the case for BDG testing for PcP, 56 where  optimal sensitivity is required to confidently exclude disease.  Given the poor  previously 57 reported sensitivity of the D-BDG when detecting PCP1 ,performance must  be determined and 58 sensitivity clarified to understand utility.  59 A performance evaluation was performed using excess clinical material, as an anonymous 60 retrospective case/control study across two centres (Public Health Wales Microbiology Cardiff 61 and the Royal Free Hospital, London) with no impact on patient management Patients were 62 initially tested for PcP (immuno-fluorescent microscopy (IF)/PcP PCR/Associates of Cape Cod 63 BDG (A-BDG)) by the local centre, based on risk factors and symptoms. D-BDG testing was 64 performed at Public Health Wales Microbiology Cardiff blinded to the diagnosis. D-BDG was 65 performed according to manufacturer’s instructions using a positivity threshold of 95pg/mL. All 66 samples (n=73) were tested in duplicate, and when required a third replicate was tested to 67 resolve discordant results. When calculating the final concentration of BDG for each sample the 68 mean value was used. There were 33 samples from PcP cases, five samples from other forms of 69 fungal disease and 35 samples from patients without IFD. 70 PcP was considered proven (n=2) if a respiratory specimen was positive by IF, probable (n=20) 71 if the patient was immuno-suppressed, had clinical signs consistent with PcP (e.g. bilateral 72 
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ground glass opacification, reduced O2 saturation) and was PcP PCR and/or A-BDG positive (15 73 positive by both, three positive by PCR only and two positive by A-BDG only). Possible PcP 74 (n=7) was classified in symptomatic cases with non-specific, or absence of chest radiology, but 75 with positive PcP PCR (n=2) or  strongly positive by A-BDG (>250pg/ml, n=5). No IFD (control) 76 patients (n=29) were classified as symptomatic cases with non-specific, or absence of chest 77 radiology with PcP PCR negativity and/or A-BDG concentrations <250pg/ml. A further five 78 control patients with evidence of other IFD (three invasive aspergillosis and two invasive 79 candidal disease) were also included. 80 When using the D-BDG the median BDG concentration for the 22 proven/probable cases of PcP 81 was 260.5pg/mL (range: 19.1->628pg/mL), compared to 198.0pg/mL (range: 26.7-82 >628pg/mL), 292.9pg/mL (range: 38.5->628pg/mL) and 52.8pg/mL (range: <9.4-306.3pg/mL) 83 for possible PcP, other IFD and No IFD, respectively. Qualitative agreement between the D-BDG 84 and ACC-BDG result, irrespective of PcP status was 73.9% (51/69 samples, 95% CI: 62.5-82.8. 85 Four samples did not have an ACC-BDG result available), generating a Kappa statistic of 0.461, 86 representing moderate/fair agreement. In relation to cases of PcP (proven/probable/possible) 87 the observed qualitative agreement was 83.9% (26/31 samples, 95% CI: 67.9-95.5. Two 88 samples did not have an ACC-BDG result available).  Of the five discordant results two were 89 positive by the D-BDG alone (Mean BDG concentration: 196.0pg/mL) and three were positive by 90 the ACC-BDG alone (Mean BDG concentration: 284.7pg/mL). One sample from a probable PcP 91 case was negative by both BDG assays, but was PCR positive. Observed agreement when testing 92 samples from the control population was 68.6% (24/35, 95% CI: 52.0-81.5). Of the 11 93 discordant results, five were positive by the D-BDG alone (Mean BDG concentration: 94 240.7pg/mL, SD±55.0) and six were positive by the ACC-BDG alone (Mean BDG concentration: 95 108.5pg/mL, SD±24.3). Five samples from control patients were positive by both BDG assays. 96 For the five cases of IFD other than PcP there was 100% agreement between the BDG assays.  97 The clinical performance when testing various populations is shown in table 1. There was a 98 trend towards improved sensitivity (36.4%, 95% CI: -0.57 to 68.8, P: 0.0913) over the previous 99 
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study, but this was not sufficient to enable PcP  to be confidently excluded when negative (LR –100 tive: 0.19). The three false negative results had mean BDG concentrations ranging from 19.1-101 67.6pg/mL, not close to the positive threshold, although in one sample 1/3 replicates did 102 generate a positive result of 128.2pg/ml, but 2/3 had a concentration of <9.4pg/mL. One false 103 negative D-BDG result was both PcP PCR and ACC-BDG positive (>500pg/mL), one was ACC-104 BDG positive (255pg/mL) but inhibitory to PCR and one was PcP PCR positive but ACC-BDG 105 negative. All false negative D-BDG results were in the non-HIV-infected population, and lower 106 sensitivity has been associated with this population.4 The performance of the D-BDG assay was 107 similar when testing cases of possible PcP (Table 1). The performance for the detection of 108 combined IFD (Sensitivity: 85.3% 95% CI: 69.9-93.6; Specificity: 72.4%, 95% CI: 54.3-85.3) was 109 similar to the previous evaluation (Sensitivity: 81.4% 95% CI: 67.4-90.3; Specificity: 78.1%, 110 95% CI: 66.6-86.5). 111 Receiver operator characteristic curve analysis generated an area under the curve of XXX, and 112 representative performance according to positivity threshold is shown in Table 2. To achieve a 113 sensitivity >90% the threshold would need to be reduced to 45pg/mL, generating a sensitivity 114 of 95.5% (95% CI: 78.2-99.2) and samples with a BDG concentration below this threshold 115 would be highly unlikely to be associated with  PcP (LR-tive> 0.12). Conversely, a threshold of 116 300pg/mL is required to achieve a specificity of 96.6% and LR+tive of 14.7 where disease can 117 be confirmed. Given that the BDG concentrations for 3/5 IFD other than PcP were also greater 118 than 300pg/.mL it was not possible to use the D-BDG assay to differentiate between different 119 fungal diseases. While there have been successful attempts to differentiate PcP infection, from 120 colonization and false positivity in controls, BDGcannot differentiate between causes of IFD. 6-8 121 aA single threshold  cannot be applied across brands, due to differences in reaction kinetics and 122 it has been noted that BDG concentrations can vary between assays.8 123 In summary, the  reported performance the D-BDG assays for the detection of PcP was 124 improved compared to the initial evaluation and is comparable to performance for other IFD.1 125 The sensitivity remains slightly below that required for it to be used to confidently exclude PcP, 126 
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although this may reflect the retrospective nature of the study. Specificity can be enhanced by 127 using a positivity threshold of 300pg/mL, but unlike previous studies this willcompromise 128 sensitivity.6 Prospective evaluation is required to confirm clinical validity.   129 
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Table 1. Performance parameters of the Dynamiker® Fungus (1-3)-β-D-Glucan Assay for the 167 diagnosis of Pneumocystis pneumonia and other invasive fungal diseases. 168 
Parameter  (n/N; %, 95% CI) 
Fungal disease Proven/Probable PCP vs NEF Proven/Probable/Possible PCP vs NEF Other IFD vs NEF Sensitivity 19/22; 86.4%,  66.7-95.3 25/29; 86.2%,  69.4-94.5 4/5; 80.0%,  37.6-96.4 Specificity  21/29; 72.4%,  54.3-85.3 21/29; 72.4%,  54.3-85.3 21/29; 72.4%,  54.3-85.3 LR +tive  3.13 3.12 2.90 LR -tive 0.19 0.19 0.28 DOR 16.47 16.42 10.36 
Key:  PcP: Pneumocystis pneumonia 169 
 IFD: Invasive fungal disease 170 
 NEF: No evidence of fungal disease 171 
LR +tive: Positive likelihood ration  172 
LR -tive: Negative likelihood ration  173 
DOR: Diagnostic Odds ratio  174   175 
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Table 2. The effect of varying the positive threshold on the clinical performance of the 176 Dynamiker® Fungus (1-3)-β-D-Glucan Assay for the detection of proven/probable 177 
Pneumocystis pneumonia versus no evidence of fungal disease 178 
Positivity Threshold (pg/mL) Performance parameter Sensitivity (%) Specificity (%) LR +tive LR-tive DOR 
20 100 17.2 1.2 <0.006a >200.0a 
45 95.5 37.9 1.5 0.12 12.5 
95 (Current) 86.4 72.4 3.1 0.19 16.5 
150 72.7 72.4 2.6 0.38 6.8 
200 54.5 79.3 2.6 0.57 4.6 
250 54.5 89.7 5.3 0.51 10.4 
300 50 96.6 14.7 0.52 28.3 
350 45.5 100 >455.0a 0.55 >827.3a 
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